Last €2.50 EUR
Change Today -0.045 / -1.77%
Volume 0.0
HTD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 9:32 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (HTD) Snapshot

Open
€2.43
Previous Close
€2.54
Day High
€2.56
Day Low
€2.43
52 Week High
04/3/14 - €3.19
52 Week Low
05/9/14 - €1.26
Market Cap
252.5M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
101.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORCEPT THERAPEUTICS INC (HTD)

corcept therapeutics inc (HTD) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (HTD) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (HTD) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, an active ingredient in Korlym, which is in Phase III study for treatment of the psychotic features of psychotic depression; and in Phase I study for the treatment of triple-negative breast cancer. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

44 Employees
Last Reported Date: 03/14/14
Founded in 1998

corcept therapeutics inc (HTD) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $925.9K
Chief Financial Officer and Secretary
Total Annual Compensation: $465.4K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $582.6K
Chief Accounting Officer, Vice President and ...
Total Annual Compensation: $328.2K
Consultant
Total Annual Compensation: $679.0K
Compensation as of Fiscal Year 2013.

corcept therapeutics inc (HTD) Key Developments

Corcept Therapeutics Incorporated Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Revenue Guidance for the Year 2014

Corcept Therapeutics Incorporated announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. The company reported net product sales of $7,282,000 compared with $2,634,000 a year ago. Loss from operations was $5,103,000 compared with $9,740,000 a year ago. Net loss and comprehensive loss was $6,006,000 compared with $10,906,000 a year ago. Basic and diluted net loss per share was $0.06 compared with $0.11 a year ago. Non- GAAP net loss was $3,901,000 compared with $8,464,000 a year ago Non-GAAP basic and diluted net loss per share as adjusted for significant non-cash expenses was $0.04 compared with $0.08 a year ago. For the nine months period, the company reported net product sales of $17,537,000 compared with $6,242,000 a year ago. Loss from operations was $24,542,000 compared with $31,466,000 a year ago. Net loss and comprehensive loss was $27,488,000 compared with $34,887,000 a year ago. Basic and diluted net loss per share was $0.27 compared with $0.35 a year ago. Non- GAAP net loss was $20,800,000 compared with $27,664,000 a year ago. Non-GAAP basic and diluted net loss per share as adjusted for significant non-cash expenses was $0.21 compared with $0.28 a year ago. The company revised the range of its 2014 revenue guidance to $25 million -27 million.

Corcept Therapeutics Incorporated to Report Q3, 2014 Results on Nov 04, 2014

Corcept Therapeutics Incorporated announced that they will report Q3, 2014 results on Nov 04, 2014

Corcept Therapeutics Incorporated, Q3 2014 Earnings Call, Nov 04, 2014

Corcept Therapeutics Incorporated, Q3 2014 Earnings Call, Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTD:GR €2.50 EUR -0.045

HTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.92.35 CHF -1.20
View Industry Companies
 

Industry Analysis

HTD

Industry Average

Valuation HTD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.